Nandrolone Decanoate 200®
Nandrolone Decanoate is the decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors.
Chemical: NANDROLONE DECANOATE 100mg/ml
Molecular Formula: C28H44O3
Molecular Weight: 428.657 g/mol
Melting point: Base 118 °C
Males: Androgen Replacement Therapy:
Test Prop is indicated for androgen replacement therapy in conditions associated with deficiency or absence of endogenous testosterone.
Primary hypogonadism: Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchiectomy.
Hypogonadotropic hypogonadism: Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
Delayed puberty: Test Prop Injection may be used to stimulate puberty in carefully selected males with clearly delayed puberty that is not secondary to other pathological disorders.
Females: Metastatic mammary cancer: Test Prop Injection may be used secondarily in women with advancing inoperable metastatic mammary cancer who are one to five years post-menopausal. It has also been used in pre-menopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.
Postpartum Breast Engorgement: as recommended by qualified physician.
Any nausea, vomiting, changes in skin color or ankle swelling should be monitored by a qualified physician, particularly in patients with a history of severe heart, liver, and kidney disease.
Androgen therapy patients receiving concurrent warfarin treatment may present with unexpected increases in the INR and/or pro-thrombin time (PT). When administered to these patients, the dosing of warfarin may need to be reduced significantly to maintain the desired INR level and reduce the risk of serious bleeding.
Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease.
Androgens may reduce clotting factors II, V, VII, and X, and may increase pro-thrombin time (PT). Patients should be instructed to report any use of warfarin and any irregular bleeding.
For Women: Women on androgen therapy should be observed for signs of virilization which may include the deepening of the voice, hirsutism, or clitoromegaly. Therapy should be discontinued upon signs of virilism to reduce the risk of irreversible virilization. Some virilizing effects may be irreversible after cessation of therapy even with concurrent administration of estrogens. Menstrual irregularities may also occur.
Androgens should be used with caution in children and adolescents who are still growing because of possible premature epiphyseal closure in males and females, precocious sexual development in pre-pubertal males, or virilization in females. Skeletal maturation should be monitored at 6-month intervals by x-ray of the hand and wrist.
Treatment of male patients over the age of approximately 50 years with androgens should be preceded by a thorough examination of the prostate and baseline measurement of serum prostate-specific antigen (PSA) concentration, since androgens may cause increased risk of prostate hypertrophy or may stimulate the growth of occult prostatic carcinoma. Periodic evaluation of prostate functions should also be performed during the course of therapy.
Dosage and Administration
Nandrolone Decanoate injection should be administered by deep intramuscular injection.
Adult dose: 25 mg to 50 mg every three weeks.